bio

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 460
            [name] => bio
            [slug] => bio
            [term_group] => 0
            [term_taxonomy_id] => 460
            [taxonomy] => post_tag
            [description] =>
            [parent] => 0
            [count] => 1
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 407
            [name] => funding-for-biotechnology
            [slug] => financing-for-biotechnology
            [term_group] => 0
            [term_taxonomy_id] => 407
            [taxonomy] => post_tag
            [description] =>
            [parent] => 0
            [count] => 2
            [filter] => raw
        )

)

Aelix and Bionaturis receive funding for the development of vaccines

14/01 Most active investors

The development of new vaccines is a lengthy and rather costly process in which it is often difficult to find funding.

Now, for tomorrow

Baker Tilly Global Deal Advisory trading as Baker Tilly Global Deal Advisory is an independent member of Baker Tilly International. Baker Tilly International Limited is an English company. Baker Tilly International does not provide professional services to its clients. Each member firm is a separate and independent legal entity, and each describes itself as such. Baker Tilly Global Deal Advisory is not the agent of Baker Tilly International and does not have the authority to bind Baker Tilly International or act on behalf of Baker Tilly International. None of Baker Tilly International, Baker Tilly Global Deal Advisory, nor any of the other Baker Tilly International member firms has any liability for the acts or omissions of the others. The Baker Tilly name and associated logo is used under licence from Baker Tilly International Limited.

bio

bio

We are together in each step

Services

Learn

Now, for tomorrow